Riskpilot← Back to searchSign inGet full accessAreos Medpharm Consulting AB
ABActiveOrg 5592357908Orrstigen 8 BEngineering activities and related technical consultancy · NACE 7112Est. 20200 employees
Revenue 2025
SEK 349K
-74% vs 2024
EBITDA margin
-112.7%
-182% vs 2024
Equity ratio
49.2%
Financial strength
Net profit 2025
SEK -16K
-106% vs 2024
| Revenue | SEK 349K | -74% |
| EBITDA | SEK -393K | -182% |
| Net profit | SEK -16K | -106% |
| Total assets | SEK 782K | -52% |
| Equity | SEK 385K | -46% |
| Employees | 0 | — |
Legal name
Areos Medpharm Consulting AB
Org number
5592357908
Legal form
Aktiebolag
NACE code
7112 · Engineering activities and related technical consultancy
Founded
8 januari 2020
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Utföra konsultuppdrag inom läkemedelsindustrin. Att sälja medicintekniska produkter till apotek och offentlig sektor.
Address
Orrstigen 8 B
Email
larsp.swenson@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 179 | 1 253 | 1 337 | 1 351 | 349 |
| Staff expenses | — | −745 | −816 | −828 | −692 |
| EBITDA | 417 | 450 | 472 | 480 | −393 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 417 | 450 | 472 | 480 | −393 |
| Net financials | — | −1 | 5 | 17 | 5 |
| Profit before tax | 311 | 336 | 355 | 368 | −12 |
| Tax | −66 | −71 | −76 | −80 | −4 |
| Net profit | 245 | 266 | 279 | 288 | −16 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 365 | 1 379 | 1 533 | 1 636 | 782 |
| Equity | 749 | 742 | 738 | 713 | 385 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 241 | 148 | 185 | 183 | 34 |
| Total debt | 241 | 148 | 185 | 183 | 34 |
EBITDA margin
-112.7%
This company
15.8%
Market median
-813% vs market
20212025
Equity ratio
49.2%
This company
38.2%
Market median
+29% vs market
20212025
Return on equity
-4.1%
This company
18.4%
Market median
-122% vs market
20212025
Net profit margin
-4.6%
This company
8.1%
Market median
-157% vs market
20212025
Asset turnover
0.45×
This company
1.12×
Market median
-60% vs market
20212025
Debt / equity
1.03×
This company
0.62×
Market median
-66% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Deputy Board Member | 2020 | |
| Deputy Board Member | 2020 | |
| Chairman | 2022 | |
| Board of Directors | 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Areos Medpharm Consulting AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna Linnea Bergvall | Deputy Board Member | 0 companies |
| Anna Linnea Bergvall | Deputy Board Member | 0 companies |
| Lars Peter Svensson | Chairman | 0 companies |
| Barbro Carina Bergvall | Board of Directors | 0 companies |